Main content area

Comparative exoproteome profiling of an invasive and a commensal Staphylococcus haemolyticus isolate

Cavanagh, Jorunn Pauline, Pain, Maria, Askarian, Fatemeh, Bruun, Jack-Ansgar, Urbarova, Ilona, Wai, Sun Nyunt, Schmidt, Frank, Johannessen, Mona
Journal of proteomics 2019 v.197 pp. 106-114
Staphylococcus haemolyticus, adhesion, antibiotic resistance, biofilm, coagulase negative staphylococci, cross infection, iron, multiple drug resistance, proteins, proteolysis, secondary infection, secretion, staphylococcal infections, vaccine development, virulence
Staphylococcus haemolyticus is a skin commensal emerging as an opportunistic pathogen. Nosocomial isolates of S. haemolyticus are the most antibiotic resistant members of the coagulase negative staphylococci (CoNS), but information about other S. haemolyticus virulence factors is scarce. Bacterial membrane vesicles (MVs) are one mediator of virulence by enabling secretion and long distance delivery of bacterial effector molecules while protecting the cargo from proteolytic degradation from the environment. We wanted to determine if the MV protein cargo of S. haemolyticus is strain specific and enriched in certain MV associated proteins compared to the totalsecretome.The present study shows that both clinical and commensal S. haemolyticus isolates produce membrane vesicles. The MV cargo of both strains was enriched in proteins involved in adhesion and acquisition of iron. The MV cargo of the clinical strain was further enriched in antimicrobial resistance proteins.Data are available via ProteomeXchange with identifier PXD010389.Clinical isolates of Staphylococcus haemolyticus are usually multidrug resistant, their main virulence factor is formation of biofilms, both factors leading to infections that are difficult to treat. We show that both clinical and commensal S. haemolyticus isolates produce membrane vesicles. Identification of staphylococcal membrane vesicles can potentially be used in novel approaches to combat staphylococcal infections, such as development of vaccines.